| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Cooperative Research Center for Vaccine Technology and Queensland Institute of Medical Research, Brisbane, Australia
Perforin and the serine protease granzymes are key effectors of CD8+ T cell granule-mediated cytotoxicity, but the requirements for their expression remain largely undefined. We show in this study that IL-2 increased the expression of perforin and granzyme A, B, and C mRNA; intracellular granzyme B protein levels; and cytolytic function in a dose-dependent manner during primary activation of murine CD8+ T cells in vitro. Two approaches showed that these responses were not a consequence of the effects of IL-2 on cell survival and proliferation. First, IL-2 enhancement of perforin and granzyme expression was equivalent in CD8+ T cells from wild-type and bcl-2 transgenic mice, although only the latter cells survived in low concentrations or the absence of added IL-2. This property of bcl-2 transgenic T cells also allowed the demonstration that induction of granzyme A, B, and C mRNA and granzyme B protein required exogenous IL-2, whereas induction of perforin and IFN-
expression did not. Second, analysis of perforin and granzyme mRNA levels in cells separated according to division number using the dye CFSE showed that the effects of IL-2 were unrelated to division number. Together, these findings indicate that IL-2 can directly regulate perforin and granzyme gene expression in CD8+ T cells independently of its effects on cell survival and proliferation.
This article has been cited by other articles:
|
|
 |
|
  N. K. Rajasagi, S. H. Kassim, C. M. Kollias, X. Zhao, R. Chervenak, and S. R. Jennings CD4+ T Cells Are Required for the Priming of CD8+ T Cells following Infection with Herpes Simplex Virus Type 1 J. Virol., May 15, 2009; 83(10): 5256 - 5268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Verdeil, K. Marquardt, C. D. Surh, and L. A. Sherman Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy PNAS, October 28, 2008; 105(43): 16683 - 16688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Redmond, M. J. Gough, B. Charbonneau, T. L. Ratliff, and A. D. Weinberg Defects in the Acquisition of CD8 T Cell Effector Function after Priming with Tumor or Soluble Antigen Can Be Overcome by the Addition of an OX40 Agonist J. Immunol., December 1, 2007; 179(11): 7244 - 7253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Jenkins, K. Kedzierska, P. C. Doherty, and S. J. Turner Heterogeneity of Effector Phenotype for Acute Phase and Memory Influenza A Virus-Specific CTL J. Immunol., July 1, 2007; 179(1): 64 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ranasinghe, S. J. Turner, C. McArthur, D. B. Sutherland, J.-H. Kim, P. C. Doherty, and I. A. Ramshaw Mucosal HIV-1 Pox Virus Prime-Boost Immunization Induces High-Avidity CD8+ T Cells with Regime-Dependent Cytokine/Granzyme B Profiles J. Immunol., February 15, 2007; 178(4): 2370 - 2379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gong and T. R. Malek Cytokine-Dependent Blimp-1 Expression in Activated T Cells Inhibits IL-2 Production J. Immunol., January 1, 2007; 178(1): 242 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kamath, J. S.M. Woodworth, and S. M. Behar Antigen-Specific CD8+ T Cells and the Development of Central Memory during Mycobacterium tuberculosis Infection J. Immunol., November 1, 2006; 177(9): 6361 - 6369. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
